Logo image
Back
A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
Journal article   Peer reviewed

A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less

Scott M Hammer, Kathleen E Squires, Michael D Hughes, Janet M Grimes, Lisa M Demeter, Judith S Currier, Joseph J Eron, Judith E Feinberg, Henry H Balfour, Lawrence R Deyton, …
The New England journal of medicine, Vol.337(11), pp.725-733
09/11/1997
DOI: 10.1056/NEJM199709113371101
PMID: 9287227

View Online

Abstract

Progress in the field of antiretroviral therapy for human immunodeficiency virus type 1 (HIV-1) infection has brought the end of the zidovudine-monotherapy era, 1 – 3 an improved understanding of the pathogenesis of HIV-1 disease, 4 – 9 demonstrations of the prognostic importance of plasma HIV-1 RNA quantification, 10 – 17 and the availability of increasingly potent therapeutic agents. Much of this progress is linked to the introduction of the HIV-protease inhibitors, drugs that inhibit the processing of Gag and Gag–Pol polyprotein precursors and thus prevent the maturation of virions. 18 – 20 Trials of HIV-protease inhibitors have shown beneficial effects on CD4 cell counts and plasma HIV-1 . . .

Details

Metrics

23 Record Views
2272 Times Cited - Web of Science
Logo image